The literature cluster reveals a maturing paradigm in which Alzheimer's Disease (AD) is reframed not merely as a proteinopathy but as a convergence point of neuroinflammatory, vascular, and cellular senescence mechanisms. Central to this trend is the reciprocal relationship between amyloid-β/tau pathology and microglial-astrocytic immune responses: amyloid accumulation triggers microglial activation, complement-mediated synaptic pruning, and astrocytic dysfunction (e.g., CLU risk allele effects reducing Clusterin and heightening inflammation), while genetic modulators like TREM2 and LAG3 govern microglial phagocytic and immune-checkpoint activity. Discoveries such as CD5L-enhanced phagocytosis and SPP1-driven senescent microglial signaling (via the SPP1-CD44 axis) point toward a therapeutic strategy centered on reprogramming innate immune clearance mechanisms rather than solely targeting amyloid deposition itself. The identification of a coordinated "Blood-Brain Barrier Senescence Unit" (astrocytes, pericytes, microglia, T cells) further signals a shift toward viewing AD as a multi-cellular, senescence-driven disorder with systemic inflammatory underpinnings.
A second major axis is the vascular-metabolic contribution to late-onset AD, evidenced by the strong thematic linkage between atherosclerosis, cerebral atherosclerosis, endothelial dysfunction, and beta-amyloid-driven pathological angiogenesis and hemodynamic changes. Beta-amyloid is positioned as a bidirectional actor—both a product of neurodegeneration and a driver of vascular pathology—inducing inflammation, endothelial injury, and abnormal cerebral blood flow that in turn accelerate amyloid and tau accumulation. The novel gene OSBPL11 exemplifies this convergence, showing co-increased expression and cellular co-localization in both atherosclerotic macrophages and AD-affected astrocytes, validated across patient samples and ApoE-/- mouse models, and now proposed as a shared therapeutic target bridging cardiovascular and neurodegenerative disease. This supports an emerging "vascular hypothesis" of late-onset AD that runs parallel to, and interacts mechanistically with, the amyloid cascade hypothesis.
Therapeutically, the trend data suggest diversification beyond anti-amyloid immunotherapy toward tau-targeted therapies, computational drug discovery for small molecules addressing amyloid, tau, and inflammation simultaneously, and apoptotic-pathway modulation via microRNA regulation. Spatial transcriptomics and single-cell approaches are enabling fine-grained mapping of microglia-astrocyte-complement crosstalk and cell-type-specific vulnerability, reflecting a broader methodological shift toward systems-level, spatially resolved disease modeling. Collectively, these entities and relationships depict AD research trending toward integrative, multi-system models—linking innate immunity, cellular senescence, vascular biology, and proteostasis—that prioritize shared molecular targets (TREM2, LAG3, SPP1, OSBPL11, complement components) applicable across neurodegenerative and cardiovascular disease boundaries.